RxDoctor Payments Data

Bernardine King, MD

Cardiovascular Disease · Gainesville, GANPI 1639145253

Payments from drug & device makers

$8,776in general payments, 2019–2025

Across 399 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Pfizer$712
  • Johnson & Johnson$698
  • Sanofi-aventis U.S. LLC$569
  • Esperion Therapeutics, Inc.$567
  • Novartis$518
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,751100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,776 in reported general payments places this provider in the 75th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$363,359
Medicare patients
830
Services billed
4,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban597$702,127
Repatha SureclickEvolocumab298$415,780
XareltoRivaroxaban156$197,571
Praluent PenAlirocumab82$113,358
MultaqDronedarone Hcl88$103,950
EntrestoSacubitril/Valsartan53$69,773
FarxigaDapagliflozin Propanediol55$52,738
BrilintaTicagrelor64$45,670
NexlizetBempedoic Acid/Ezetimibe32$37,190
Metoprolol Succinate894$14,017
VascepaIcosapent Ethyl22$13,434
Fenofibrate34$6,973
Ezetimibe301$5,460
Clonidine37$5,226
Rosuvastatin Calcium407$4,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$712$702,127597 claims
Johnson & JohnsonXarelto$698$197,571156 claims
Sanofi-aventis U.S. LLCMultaq$569$103,95088 claims
AstraZenecaFarxiga, Brilinta$464$98,407119 claims
NovartisEntresto$518$69,77353 claims
Esperion Therapeutics, Inc.Nexlizet$567$37,19032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →